Hirose Takahisa, Chen Ching-Chu, Ahn Kyu Jeung, Kiljański Jacek
Division of Diabetes, Metabolism and Endocrinology, Department of Medicine, Toho University Graduate School of Medicine, Tokyo, Japan.
Division of Endocrinology and Metabolism, Department of Medicine, China Medical University Hospital, Taichung, Taiwan.
Diabetes Ther. 2019 Jun;10(3):805-833. doi: 10.1007/s13300-019-0613-7. Epub 2019 Apr 24.
Insulin glargine (IGlar) 100 U/mL (IGlar-100) is widely used in East Asian countries for the treatment of type 2 diabetes mellitus (T2DM) and is the gold standard of basal insulin treatment. In this review we summarize key information about clinical experience with IGlar-100 in East Asian patients with T2DM, including findings from clinical trials and postmarketing studies. We also provide recommendations and opinions on the optimal use of IGlar-100 in this population. The findings from the studies highlighted in our review indicate that IGlar-100 can be a suitable treatment option for East Asians with T2DM, from initial therapy in combination with oral antihyperglycemic medications through to different combinations and intensification models. FUNDING: Eli Lilly and Company.
甘精胰岛素（IGlar）100 U/mL（IGlar-100）在东亚国家被广泛用于治疗2型糖尿病（T2DM），是基础胰岛素治疗的金标准。在本综述中，我们总结了东亚T2DM患者使用IGlar-100的临床经验的关键信息，包括临床试验和上市后研究的结果。我们还就该人群中IGlar-100的最佳使用提供建议和意见。我们综述中强调的研究结果表明，从与口服降糖药物联合的初始治疗到不同的联合治疗和强化治疗模式，IGlar-100可以是东亚T2DM患者的合适治疗选择。资助：礼来公司。
